Trump's psychedelics executive order could speed federal support for mental health treatments, including pediatric research on MDMA, psilocybin and ketamine

Trump's executive order on expanding access to innovative medical treatments could accelerate federal pathways for psychedelic-assisted care, including potential research and clinical use in children and adolescents. Mental health conditions such as PTSD, depression and suicidality sit at the center of the policy case for faster development. MDMA, psilocybin and ketamine are the main substances linked to this shift. The order may strengthen pressure on regulators and agencies to support trials, streamline access programs and reconsider age limits where evidence and clinical need are strong. Pediatric psychiatry becomes especially notable because severe youth mental health crises often have limited effective treatments. Federal backing would matter beyond one administration because it could normalize psychedelics inside mainstream medicine, expand investment and push hospitals, researchers and drug developers to prepare for broader therapeutic adoption. Safety, evidence standards and careful patient selection remain decisive as policy momentum grows.